Welcome to Central Library, SUST

Analogue-based drug discovery III / (Record no. 63890)

MARC details
000 -LEADER
fixed length control field 05790cam a2200841Ii 4500
001 - CONTROL NUMBER
control field sulb-eb0032238
003 - CONTROL NUMBER IDENTIFIER
control field BD-SySUS
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20170713221325.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu|||unuuu
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130204t20132013gw ac ob 001 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency DG1
Language of cataloging eng
Description conventions rda
-- pn
Transcribing agency DG1
Modifying agency EBLCP
-- N$T
-- MHW
-- YDXCP
-- COO
-- IDEBK
-- E7B
-- NOC
-- OCLCF
-- IUL
-- SCB
-- OCLCQ
-- CDX
-- NKT
-- OCLCQ
-- BD-SySUS
019 ## -
-- 828869678
-- 828896125
-- 961601655
-- 962705463
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783527651085
Qualifying information (electronic bk.)
International Standard Book Number 352765108X
Qualifying information (electronic bk.)
International Standard Book Number 9783527651115
Qualifying information (electronic bk.)
International Standard Book Number 352765111X
Qualifying information (electronic bk.)
International Standard Book Number 9781299241206
Qualifying information (MyiLibrary)
International Standard Book Number 1299241204
Qualifying information (MyiLibrary)
Canceled/invalid ISBN 9783527330737
Canceled/invalid ISBN 3527330739
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier AU@
System control number 000050562533
OCLC library identifier AU@
System control number 000053030546
OCLC library identifier DKDLA
System control number 820120-katalog:000655918
OCLC library identifier NLGGC
System control number 382514440
OCLC library identifier NZ1
System control number 15340091
OCLC library identifier DEBBG
System control number BV043395341
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)826637765
Canceled/invalid control number (OCoLC)828869678
-- (OCoLC)828896125
-- (OCoLC)961601655
-- (OCoLC)962705463
037 ## - SOURCE OF ACQUISITION
Stock number 455370
Source of stock number/acquisition MIL
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM301.25
Item number .A53 2013
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 023000
Source bisacsh
Subject category code MED
Subject category code subdivision 058170
Source bisacsh
Subject category code MED
Subject category code subdivision 071000
Source bisacsh
Subject category code MED
Subject category code subdivision 072000
Source bisacsh
Subject category code HEA
Source eflch
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.1/9
Edition number 23
049 ## - LOCAL HOLDINGS (OCLC)
Holding library MAIN
245 00 - TITLE STATEMENT
Title Analogue-based drug discovery III /
Statement of responsibility, etc. edited by János Fischer, C. Robin Ganellin, David P. Rotella.
246 3# - VARYING FORM OF TITLE
Title proper/short title Analogue-based drug discovery 3
Title proper/short title Analog-based drug discovery III
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Weinheim :
Name of producer, publisher, distributor, manufacturer Wiley-VCH,
Date of production, publication, distribution, manufacture, or copyright notice [2013]
Date of production, publication, distribution, manufacture, or copyright notice ©2013
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (xviii, 385 pages) :
Other physical details illustrations, portraits
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Online resource; title page from PDF title page (viewed June 30, 2014).
505 00 - FORMATTED CONTENTS NOTE
Title General Aspects. Pioneer and Analogue Drugs /
Statement of responsibility Janos Fischer, C Robin Ganellin, David P Rotella --
Title Competition in the Pharmaceutical Drug Development /
Statement of responsibility Christian Tyrchan, Fabrizio Giordanetto --
Title Metabolic Stability and Analogue-Based Drug Discovery /
Statement of responsibility Amit S Kalgutkar, Antonia F Stepan --
Title Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders /
Statement of responsibility Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon --
Title Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes /
Statement of responsibility A Ganesan --
Title Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs /
Statement of responsibility Joseph A Jakubowski, Atsuhiro Sugidachi --
Title Selective Estrogen Receptor Modulators /
Statement of responsibility Amarjit Luniwal, Rachael Jetson, Paul Erhardt --
Title Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists /
Statement of responsibility Kazumi Kondo, Hidenori Ogawa --
Title The Development of Cysteinyl Leukotriene Receptor Antagonists /
Statement of responsibility Peter R Bernstein --
Title Case Studies. The Discovery of Dabigatran Etexilate /
Statement of responsibility Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen --
Title The Discovery of Citalopram and Its Refinement to Escitalopram /
Statement of responsibility Klaus P Bogeso, Connie Sanchez --
Title Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol /
Statement of responsibility Helmut Buschmann --
Title Novel Taxanes: Cabazitaxel Case Study /
Statement of responsibility Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud --
Title Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design /
Statement of responsibility Srikanth Venkatraman, Andrew Prongay, George F Njoroge --
Title A New-Generation Uric Acid Production Inhibitor: Febuxostat /
Statement of responsibility Ken Okamoto, Shiro Kondo, Takeshi Nishino.
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
520 ## - SUMMARY, ETC.
Summary, etc. "Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug development.
Topical term or geographic name as entry element MEDICAL
General subdivision Drug Guides.
Source of heading or term bisacsh
Topical term or geographic name as entry element MEDICAL
General subdivision Nursing
-- Pharmacology.
Source of heading or term bisacsh
Topical term or geographic name as entry element MEDICAL
General subdivision Pharmacology.
Source of heading or term bisacsh
Topical term or geographic name as entry element MEDICAL
General subdivision Pharmacy.
Source of heading or term bisacsh
Topical term or geographic name as entry element Drug development.
Source of heading or term fast
Authority record control number (OCoLC)fst00898670
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Genre/form data or focus term Electronic books.
Source of term local
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Fischer, János,
Relator term editor.
Personal name Ganellin, C. R.
Fuller form of name (C. Robin),
Relator term editor.
Personal name Rotella, David P.,
Relator term editor.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
Title Analogue-based drug discovery III.
Place, publisher, and date of publication Weinheim : Wiley-VCH, [2013]
International Standard Book Number 9783527330737
Record control number (OCoLC)825555931
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://onlinelibrary.wiley.com/book/10.1002/9783527651085">http://onlinelibrary.wiley.com/book/10.1002/9783527651085</a>
Public note Wiley Online Library [Free Download only for SUST IP]
938 ## -
-- Coutts Information Services
-- COUT
-- 24876696
-- 130.00 GBP
-- EBL - Ebook Library
-- EBLB
-- EBL1123660
-- ebrary
-- EBRY
-- ebr10662582
-- EBSCOhost
-- EBSC
-- 542882
-- Ingram Digital eBook Collection
-- IDEB
-- cis24876696
-- YBP Library Services
-- YANK
-- 9985301
-- YBP Library Services
-- YANK
-- 10226219
-- YBP Library Services
-- YANK
-- 10247713
994 ## -
-- 92
-- DG1

No items available.